Arlene Naranjo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1310834/publications.pdf

Version: 2024-02-01

107	4,300	109137 35	118652 62
papers	citations	h-index	g-index

109	109	109	4783
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2022, , e29616.	0.8	1
2	Expression of neuroblastomaâ€related genes in bone marrow at end of highâ€risk neuroblastoma therapy. Pediatric Blood and Cancer, 2022, , e29719.	0.8	0
3	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2022, 40, 10027-10027.	0.8	0
4	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2022, 40, 10003-10003.	0.8	6
5	Predictors of differential outcomes according to response to induction chemotherapy in high-risk neuroblastoma.. Journal of Clinical Oncology, 2022, 40, 10032-10032.	0.8	0
6	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Childrenâ€™s Oncology Group (COG) risk stratification.. Journal of Clinical Oncology, 2022, 40, 10013-10013.	0.8	0
7	Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Childrenâ€™s Oncology Group clinical trials.. Journal of Clinical Oncology, 2022, 40, 10005-10005.	0.8	0
8	Clinical and biological features prognostic of survival after relapse of INRGSS-stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.. Journal of Clinical Oncology, 2022, 40, 10044-10044.	0.8	0
9	Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma.. Journal of Clinical Oncology, 2022, 40, 10043-10043.	0.8	0
10	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	0.8	11
11	Poverty and Targeted Immunotherapy: Survival in Childrenâ€™s Oncology Group Clinical Trials for High-Risk Neuroblastoma. Journal of the National Cancer Institute, 2021, 113, 282-291.	3.0	33
12	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	3.2	95
13	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy, 2021, 27, 490.e1-490.e8.	0.6	14
14	Racial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.. Journal of Clinical Oncology, 2021, 39, 10036-10036.	0.8	0
15	Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.. Journal of Clinical Oncology, 2021, 39, 10039-10039.	0.8	1
16	A safety and feasibility trial of ¹³¹Iâ€MIBG in newly diagnosed highâ€risk neuroblastoma: A Children's Oncology Group study. Pediatric Blood and Cancer, 2021, 68, e29117.	0.8	17
17	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	0.8	174
18	Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Network Open, 2021, 4, e2116248.	2.8	5

#	Article	IF	Citations
19	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	2.1	10
20	Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clinical Cancer Informatics, 2021, 5, 1181-1188.	1.0	3
21	The ganglioside G_{D2} as a circulating tumor biomarker for neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28031.	0.8	30
22	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	5.8	87
23	Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clinical Cancer Informatics, 2020, 4, 895-905.	1.0	36
24	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	0.8	0
25	Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Childrenâ€™s Oncology Group ANBL0532 Study. Journal of Clinical Oncology, 2020, 38, 2741-2752.	0.8	36
26	Association of heterogeneous MYCN amplification with clinical features, biological characteristicsÂand outcomes in neuroblastoma: A report from the Children's Oncology Group. European Journal of Cancer, 2020, 133, 112-119.	1.3	13
27	MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020, 11, 913.	5.8	66
28	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	0.8	98
29	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Journal of Clinical Oncology, 2020, 38, 1906-1918.	0.8	41
30	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients â‰¥18 months with unfavorable histology and without MYCN amplification: A Childrenâ€™s Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10502-10502.	0.8	0
31	Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Childrenâ€™s Oncology Group (COG) ANBL0032.. Journal of Clinical Oncology, 2020, 38, 10523-10523.	0.8	0
32	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	0.8	61
33	Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Childrenâ€™s Oncology Group. Cancer Epidemiology, 2019, 61, 165-171.	0.8	6
34	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clinical Cancer Research, 2019, 25, 6044-6051.	3.2	20
35	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 746.	3.8	220
36	Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2019, 41, 222-227.	0.3	17

#	Article	IF	Citations
37	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 115-124.	0.8	45
38	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). European Journal of Cancer, 2019, 112, 66-79.	1.3	49
39	Prohibitin is a prognostic marker and therapeutic target to block chemotherapy resistance in Wilmsâ€™ tumor. JCI Insight, 2019, 4, .	2.3	21
40	Poverty and survival in targeted immunotherapy clinical trials.. Journal of Clinical Oncology, 2019, 37, 10034-10034.	0.8	1
41	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	0.8	1
42	Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 292-305.	3.3	54
43	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research, 2018, 24, 189-196.	3.2	45
44	Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Childrenâ€™s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. Journal of Nuclear Medicine, 2018, 59, 502-508.	2.8	52
45	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. The Lancet Child and Adolescent Health, 2018, 2, 25-34.	2.7	38
46	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clinical Cancer Informatics, 2018, 2, 1-15.	1.0	20
47	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Childrenâ€™s Oncology Group Study ANBL0931. Frontiers in Immunology, 2018, 9, 1355.	2.2	66
48	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2018, 36, 10508-10508.	0.8	3
49	G_{D2} as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).. Journal of Clinical Oncology, 2018, 36, 10538-10538.	0.8	2
50	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	0.8	31
51	Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2018, 36, 10532-10532.	0.8	0
52	Irinotecanâ€“temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957.	5.1	205
53	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26545.	0.8	30
54	Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2017, 72, 177-185.	1.3	59

#	Article	IF	Citations
55	Historical time to disease progression and progressionâ€free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group earlyâ€phase trials. Cancer, 2017, 123, 4914-4923.	2.0	108
56	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 675.	2.2	18
57	Surgical protocol violations in children with renal tumors provides an opportunity to improve pediatric cancer care: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1905-1910.	0.8	39
58	A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Childrenâ€™s Oncology Group. Cancer Causes and Control, 2016, 27, 1209-1218.	0.8	8
59	Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma. American Journal of Pathology, 2016, 186, 3040-3053.	1.9	18
60	Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. Journal of Clinical Oncology, 2016, 34, 740-746.	0.8	37
61	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Childrenâ€™s Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 474-481.	3.3	19
62	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10502-10502.	0.8	4
63	Association of age at diagnosis and stage of disease with ATRX mutations in neuroblastoma.. Journal of Clinical Oncology, 2016, 34, 10525-10525.	0.8	2
64	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	0.8	3
65	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	0.8	17
66	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	0.8	31
67	Second malignancies in patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project.. Journal of Clinical Oncology, 2016, 34, 10547-10547.	0.8	0
68	Pharmacogenetics of treatment response in patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2016, 34, 10560-10560.	0.8	0
69	Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10526-10526.	0.8	0
70	Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. Cancer, 2015, 121, 2457-2464.	2.0	92
71	Impact of Post-Induction Curie Scores in High-Risk Neuroblastoma. Biology of Blood and Marrow Transplantation, 2015, 21, S107.	2.0	6
72	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	9.4	451

#	Article	IF	Citations
73	Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Childrenâ€™s Oncology Group. Pediatric Radiology, 2015, 45, 166-172.	1.1	45
74	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10017-10017.	0.8	7
75	Vesicular monoamine transporter protein expression in neuroblastoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10043-10043.	0.8	0
76	Second malignancies in neuroblastoma patients: A report from the International Neuroblastoma Risk Group.. Journal of Clinical Oncology, 2015, 33, 10019-10019.	0.8	0
77	Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas. , 2015, , .		0
78	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. Pediatric and Developmental Pathology, 2014, 17, 441-449.	0.5	35
79	Clear cell sarcoma of the kidney demonstrates an embryonic signature indicative of a primitive nephrogenic origin. Genes Chromosomes and Cancer, 2014, 53, 381-391.	1.5	32
80	Inter-rater reliability of surgical reviews for AREN03B2: A COG renal tumor committee study. Journal of Pediatric Surgery, 2014, 49, 154-158.	0.8	8
81	Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: Implications for central venous catheter placement. Journal of Pediatric Urology, 2014, 10, 969-973.	0.6	6
82	Race Disparities in Peptide Profiles of North American and Kenyan Wilms Tumor Specimens. Journal of the American College of Surgeons, 2014, 218, 707-720.	0.2	26
83	Real-time central review: A report of the first 3,000 patients enrolled on the Childrenâ€™s Oncology Group Renal Tumor Biology and Risk Stratification protocol AREN03B2.. Journal of Clinical Oncology, 2014, 32, 10000-10000.	0.8	8
84	Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Childrenâ€™s Oncology Group study ANBL0531.. Journal of Clinical Oncology, 2014, 32, 10006-10006.	0.8	6
85	Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients.. Journal of Clinical Oncology, 2014, 32, 10034-10034.	0.8	3
86	Urinary metabolite profiling by nuclear magnetic resonance spectroscopy to distinguish control patients from Wilms tumor (WT) and WT tumor by stage.. Journal of Clinical Oncology, 2014, 32, e21013-e21013.	0.8	2
87	Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.. Journal of Clinical Oncology, 2014, 32, 10029-10029.	0.8	1
88	Validation of postinduction Curie scores in high-risk neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 10031-10031.	0.8	1
89	Peripheral neuroblastic tumors with genotypeâ€“phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatric Blood and Cancer, 2013, 60, 363-370.	0.8	25
90	Primary nephrectomy and intraoperative tumor spill: Report from the Children's Oncology Group (COG) renal tumors committee. Journal of Pediatric Surgery, 2013, 48, 34-38.	0.8	62

#	Article	IF	Citations
91	Children's Oncology Group's 2013 blueprint for research: Renal tumors. Pediatric Blood and Cancer, 2013, 60, 994-1000.	0.8	140
92	Extending the State-Space Model to Accommodate Missing Values in Responses and Covariates. Journal of the American Statistical Association, 2013, 108, 202-216.	1.8	5
93	Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Childrenâ€™s Oncology Group. Journal of Nuclear Medicine, 2013, 54, 541-548.	2.8	169
94	Detection of Preoperative Wilms Tumor Rupture with CT: A Report from the Childrenâ€™s Oncology Group. Radiology, 2013, 266, 610-617.	3.6	51
95	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. Cancer, 2013, 119, 3718-3726.	2.0	67
96	A genome-wide association study identifies susceptibility loci for Wilms tumor. Nature Genetics, 2012, 44, 681-684.	9.4	72
97	A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants. Annals of Surgery, 2012, 256, 573-580.	2.1	152
98	Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. Cancer Research, 2012, 72, 4714-4723.	0.4	35
99	Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: A Pediatric Oncology Group study: A Report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 902-907.	0.8	26
100	Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 4351-4357.	0.8	124
101	Comparison of ¹²³Iâ€metaiodobenzylguanidine (MIBG) and ¹³¹Iâ€MIBG semiâ€quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 56, 1041-1045.	0.8	40
102	miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. Clinical Cancer Research, 2011, 17, 7684-7692.	3.2	92
103	Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2011, 17, 6858-6866.	3.2	88
104	CASZ1b, the Short Isoform of CASZ1 Gene, Coexpresses with CASZ1a during Neurogenesis and Suppresses Neuroblastoma Cell Growth. PLoS ONE, 2011, 6, e18557.	1.1	32
105	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood and Cancer, 2009, 53, 563-569.	0.8	79
106	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	5.1	176
107	Inferences about the scale parameter of the gamma distribution based on data mixed from censoring and grouping. Statistics and Probability Letters, 2003, 62, 229-243.	0.4	3